{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:16:34Z","timestamp":1790741794284,"version":"4.1.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Tuberculosis disproportionately affects low- and middle-income countries (LMICs), where gold standard molecular diagnostic assays like Xpert MTB\/RIF are relatively frequently inaccessible. A novel rapid molecular diagnostic test (nLRDT), which can test tongue swab samples, and is more suitable for decentralised primary healthcare settings, has been developed and is currently undergoing preclinical validation. This study evaluated the early cost-effectiveness of this nLRDT vs. Xpert MTB\/RIF for diagnosing pulmonary tuberculosis in rural Philippine primary healthcare settings. A hybrid decision tree and Markov model-based cost-effectiveness analysis was conducted from health provider and societal perspectives. Parameters were taken from relevant literature, national-level data, and expert opinion. Costs were expressed in 2024 US dollars and cost-effectiveness evaluated by comparing incremental cost-effectiveness ratios with willingness-to-pay threshold estimates. An estimated willingness-to-pay (WTP) threshold of $1,357 per quality-adjusted life year (QALY) was used. The nLRDT was cost-effective with sputum samples, from both perspectives, with net monetary benefits (NMBs) of $26.62 (societal perspective) and $19.21 (provider perspective) at the WTP threshold of $1,357. Similarly, the nLRDT was estimated to be cost-effective for tongue swab samples from both perspectives, with NMBs of $43.81 (societal) and $24.79 (provider). Sensitivity and scenario analyses identified the specificity of nLRDT as the key driver of cost-effectiveness, with cost-effectiveness maintained at greater WTP thresholds and varying combinations of test performance characteristics. Our findings suggest the nLRDT can be a cost-effective diagnostic tool in rural Philippines, and possibly other similar, contexts. This has positive research, industry, and policymaking implications.<\/jats:p>","DOI":"10.1371\/journal.pgph.0005364","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:25:49Z","timestamp":1761672349000},"page":"e0005364","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early cost-effectiveness analysis of a novel rapid diagnostic test for tuberculosis in rural Philippine settings"],"prefix":"10.1371","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5411-9723","authenticated-orcid":true,"given":"Aren","family":"Sargood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Ortal-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusheng","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-039X","authenticated-orcid":true,"given":"Chris","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"pgph.0005364.ref001","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9050385","article-title":"Mycobacterium tuberculosis pathogenesis, infection prevention and treatment","volume":"9","author":"R Miggiano","year":"2020","journal-title":"Pathogens"},{"issue":"6","key":"pgph.0005364.ref002","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.mpmed.2008.03.008","article-title":"Clinical tuberculosis","volume":"36","author":"RD Barker","year":"2008","journal-title":"Medicine"},{"key":"pgph.0005364.ref003","unstructured":"World Health Organization. Tuberculosis. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis"},{"issue":"4","key":"pgph.0005364.ref004","doi-asserted-by":"crossref","first-page":"2100361","DOI":"10.1183\/13993003.00361-2021","article-title":"New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization","volume":"57","author":"K Viney","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"pgph.0005364.ref005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13643-020-01493-5","article-title":"Systematic review of therapeutic outcomes of multidrug resistant tuberculosis and their predictors in adults receiving integrated treatment of tuberculosis and human immuno-deficiency virus in low- and middle-income countries: a study protocol","volume":"9","author":"BM Kadia","year":"2020","journal-title":"Syst Rev"},{"issue":"1","key":"pgph.0005364.ref006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1473-3099(23)00390-0","article-title":"The social drivers of tuberculosis, reconfirmed","volume":"24","author":"A Trajman","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pgph.0005364.ref007","article-title":"Integrating tuberculosis and noncommunicable diseases care in low- and middle-income countries (LMICs): A systematic review","volume":"19","author":"CD Foo","year":"2022","journal-title":"PLoS Med"},{"key":"pgph.0005364.ref008","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/1756-0500-6-291","article-title":"Comparison of direct versus concentrated smear microscopy in detection of pulmonary tuberculosis","volume":"6","author":"MKM Uddin","year":"2013","journal-title":"BMC Res Notes"},{"key":"pgph.0005364.ref009","unstructured":"World Health Organization. The End TB Strategy. n.d. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/the-end-tb-strategy"},{"key":"pgph.0005364.ref010","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiz097","article-title":"Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles","volume":"220","author":"CM Denkinger","year":"2019","journal-title":"J Infect Dis"},{"issue":"1","key":"pgph.0005364.ref011","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1186\/s12879-016-2039-4","article-title":"Performance of the G4 Xpert\u00ae MTB\/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: a retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settings","volume":"16","author":"NJ Dharan","year":"2016","journal-title":"BMC Infect Dis"},{"key":"pgph.0005364.ref012","volume-title":"Global Tuberculosis Report 2023 Fact Sheet","author":"World Health Organization","year":"2023"},{"key":"pgph.0005364.ref013","volume-title":"Global Tuberculosis Report 2023: The Second United Nations High-Level Meeting on TB: New Global Pledge to End the TB Epidemic","author":"World Health Organization","year":"2023"},{"key":"pgph.0005364.ref014","article-title":"Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis","author":"M Schito","year":"2012","journal-title":"J Infect Dis"},{"issue":"7","key":"pgph.0005364.ref015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058388","article-title":"Xpert Ultra stool testing to diagnose tuberculosis in children in Ethiopia and Indonesia: a model-based cost-effectiveness analysis","volume":"12","author":"N Mafirakureva","year":"2022","journal-title":"BMJ Open"},{"key":"pgph.0005364.ref016","volume-title":"Meeting report: High priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting","author":"World Health Organization","year":"2024"},{"issue":"1","key":"pgph.0005364.ref017","doi-asserted-by":"crossref","first-page":"16976","DOI":"10.1038\/s41598-020-73981-6","article-title":"Ultrasensitive detection of Mycobacterium tuberculosis by a rapid and specific probe-triggered one-step, simultaneous DNA hybridization and isothermal amplification combined with a lateral flow dipstick","volume":"10","author":"W Jaroenram","year":"2020","journal-title":"Sci Rep"},{"key":"pgph.0005364.ref018","article-title":"Cost analysis of smear microscopy and the Xpert assay for tuberculosis diagnosis: average turnaround time","volume":"53","author":"LJA Figueredo","year":"2020","journal-title":"Rev Soc Bras Med Trop"},{"key":"pgph.0005364.ref019","unstructured":"Worldometer. Philippines Population 2024. n.d. https:\/\/www.worldometers.info\/world-population\/philippines-population\/#:~:text=thePhilippinespopulationisequivalent,1%2C019peoplepermi2).&text=ThemedianageinthePhilippinesis25.0years"},{"key":"pgph.0005364.ref020","unstructured":"International Fund for Agricultural Development. Philippines. n.d. https:\/\/www.ifad.org\/en\/web\/operations\/w\/country\/philippines"},{"key":"pgph.0005364.ref021","volume-title":"Global Tuberculosis Report 2022","author":"World Health Organization","year":"2022"},{"key":"pgph.0005364.ref022","unstructured":"World Health Organization. WHO TB Country Profile: Philippines. 2024. https:\/\/worldhealthorg.shinyapps.io\/tb_profiles\/?_inputs_&entity_type=%22country%22&iso2=%22PH%22&lan=%22EN%22"},{"key":"pgph.0005364.ref023","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jix391","article-title":"Using Patient Pathway Analysis to Design Patient-centered Referral Networks for Diagnosis and Treatment of Tuberculosis: The Case of the Philippines","volume":"216","author":"C Garfin","year":"2017","journal-title":"J Infect Dis"},{"key":"pgph.0005364.ref024","volume-title":"NTP Manual of Procedures 6th Edition","author":"Republic of the Philippines National Tuberculosis Control Program","year":"2021"},{"key":"pgph.0005364.ref025","author":"O Govik","year":"2024"},{"issue":"2","key":"pgph.0005364.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264689","article-title":"Expansion of social protection is necessary towards zero catastrophic costs due to TB: The first national TB patient cost survey in the Philippines","volume":"17","author":"JL Florentino","year":"2022","journal-title":"PLoS One"},{"key":"pgph.0005364.ref027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/CEOR.S350606","article-title":"Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand","volume":"14","author":"N Chitpim","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"key":"pgph.0005364.ref028","unstructured":"Republic of the Philippines Department of Health. About San Lazaro Hospital. n.d. https:\/\/slh.doh.gov.ph\/transparency\/about-san-lazaro-hospital"},{"key":"pgph.0005364.ref029","doi-asserted-by":"crossref","unstructured":"Ama MCG, Garfin AMCG, Basilio RP, Dayrit-Halum CB, Theng NY, Butcon JV. High burden of isoniazid resistance - findings from the 2018 Philippine tuberculosis drug resistance survey. 2024.","DOI":"10.2139\/ssrn.4719075"},{"issue":"11","key":"pgph.0005364.ref030","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40273-020-00937-z","article-title":"Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers","volume":"38","author":"R Gidwani","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"pgph.0005364.ref031","unstructured":"United Nations. Life Expectancy - Population Division - Abridged Life Table - Both Sexes. n.d. https:\/\/population.un.org\/wpp\/Download\/Standard\/Mortality\/"},{"issue":"6","key":"pgph.0005364.ref032","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00162-6","article-title":"Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures","volume":"11","author":"A Pichon-Riviere","year":"2023","journal-title":"Lancet Glob Health"},{"key":"pgph.0005364.ref033","volume-title":"Philippine HTA Methods Guide - Health Technology Assessment","author":"Health Technology Assessment Unit - Department of Health Philippines","year":"2020"},{"key":"pgph.0005364.ref034","doi-asserted-by":"crossref","first-page":"100389","DOI":"10.1016\/j.lansea.2024.100389","article-title":"Cost-effectiveness analysis of a multiplex lateral flow rapid diagnostic test for acute non-malarial febrile illness in rural Cambodia and Bangladesh","volume":"23","author":"R Chew","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"pgph.0005364.ref035","unstructured":"Sims A. Rdecision: Decision Analytic Modelling in Health Economics. n.d. https:\/\/cran.r-project.org\/web\/packages\/rdecision\/index.html"},{"issue":"2","key":"pgph.0005364.ref036","first-page":"11","article-title":"The tuberculosis profile of the Philippines, 2003-2011: advancing DOTS and beyond","volume":"4","author":"R Vianzon","year":"2013","journal-title":"Western Pac Surveill Response J"},{"issue":"5","key":"pgph.0005364.ref037","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5588\/ijtld.21.0622","article-title":"Cost of TB prevention and treatment in the Philippines in 2017","volume":"26","author":"TPJ Capeding","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"pgph.0005364.ref038","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12890-018-0628-2","article-title":"Delays to treatment initiation is associated with tuberculosis treatment outcomes among patients on directly observed treatment short course in Southwest Ethiopia: a follow-up study","volume":"18","author":"A Asres","year":"2018","journal-title":"BMC Pulm Med"},{"key":"pgph.0005364.ref039","unstructured":"World Bank. Current health expenditure (% of GDP). n.d. https:\/\/data.worldbank.org\/indicator\/SH.XPD.CHEX.GD.ZS"},{"issue":"1","key":"pgph.0005364.ref040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/eb-2012-100645","article-title":"Principles for high-quality, high-value testing","volume":"18","author":"M Power","year":"2013","journal-title":"Evid Based Med"},{"issue":"7","key":"pgph.0005364.ref041","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00421-22","article-title":"Accuracy of Tongue Swab Testing Using Xpert MTB-RIF Ultra for Tuberculosis Diagnosis","volume":"60","author":"A Andama","year":"2022","journal-title":"J Clin Microbiol"},{"issue":"6","key":"pgph.0005364.ref042","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2217\/cer.15.41","article-title":"The importance of test accuracy in economic evaluations of companion diagnostics","volume":"4","author":"L San Miguel","year":"2015","journal-title":"J Comp Eff Res"},{"issue":"12","key":"pgph.0005364.ref043","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1016\/j.jaip.2021.10.006","article-title":"A Practical Guide to Understanding Cost-Effectiveness Analyses","volume":"9","author":"M Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"pgph.0005364.ref044","unstructured":"Government of New Zealand. Prescription for pharmacoeconomic analysis - 10. Sensitivity analysis. 2020. https:\/\/pharmac.govt.nz\/medicine-funding-and-supply\/the-funding-process\/policies-manuals-and-processes\/economic-analysis\/prescription-for-pharmacoeconomic-analysis-methods-for-cost-utility-analysis\/10-sensitivity-analysis"},{"issue":"1","key":"pgph.0005364.ref045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","volume":"25","author":"D Husereau","year":"2022","journal-title":"Value Health"},{"issue":"2","key":"pgph.0005364.ref046","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00340-3","article-title":"Do not blindly trust negative diagnostic test results!","volume":"5","author":"C Buchta","year":"2024","journal-title":"Lancet Microbe"},{"key":"pgph.0005364.ref047","article-title":"Culture is an imperfect and heterogeneous reference standard in pediatric tuberculosis","author":"AR DiNardo","year":"2016","journal-title":"Tuberculosis (Edinb)"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0005364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:25:58Z","timestamp":1761672358000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0005364"}},"subtitle":[],"editor":[{"given":"Graeme","family":"Hoddinott,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0005364","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}